Top 10 Private Equity Investors in Biotechnology, Pharma & Life Sciences
| Rank | Investor Name |
|---|---|
| 1 | RA Capital Management |
| 2 | Casdin Capital |
| 3 | Eli Lilly and Company |
| 4 | Janus Henderson Investors |
| 5 | Wellington Management |
| 6 | Cormorant Asset Management |
| 7 | Redmile Group |
| 8 | Logos Capital |
| 9 | Deerfield Management |
| 10 | Bristol-Myers Squibb |
Crossover funds that moved down from public markets appear alongside the traditional buyout franchises. Platform science and pharma partnership appetite drive the category, with specialist funds leading most rounds. These are buyers and control investors. This list is most relevant if you are selling the company, recapitalizing, or seeking a majority partner.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Create a free account and get the contacts for the investors above.
Rankings cover January 2025 to July 2026 investment activity in US and Canada companies. Seed and early-stage rankings measure deal participation, not suitability for every raise.